Immunic Inc. Announces New Stock Appreciation Rights Plan for Employees and Executives, Pending Shareholder Approval
Immunic Inc. has announced a new compensation plan authorized by its Board of Directors on July 7, 2025, involving the issuance of up to 35,000,000 stock appreciation rights (SARs) to its employees and executive officers. Of this total, 22,015,000 SARs are allocated to executive officers. The SARs, intended to be settled in shares of the company's common stock, are contingent upon stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to accommodate the necessary number of shares. The exercise price for each SAR is set at $0.77, the closing price of the stock on the authorization date. The SARs become exercisable from August 1, 2026, with specific conditions tied to the exercise of the company's series A and B purchase warrants and the issuance of stock or warrants in relation to the company's January 2024 private placement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001008), on July 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。